Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/17801
Title: | Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. | Austin Authors: | Tang, Monica;Price, Timothy Jay;Shapiro, Jeremy;Gibbs, Peter;Haller, Daniel G;Arnold, Dirk;Peeters, Marc;Segelov, Eva;Roy, Amitesh;Tebbutt, Niall C ;Pavlakis, Nick;Karapetis, Chris;Burge, Matthew | Affiliation: | NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia Medical Oncology, Cabrini Hospital, Malvern, Australia Medical Oncology, Monash University, Melbourne, Australia Systems Biology and Personalised Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia Medical Oncology, Flinders University, Bedford Park, Australia Abramson Cancer Center at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Medical Oncology, Asklepios Tumorzentrum Hamburg, Hamburg, Germany Medical Oncology, University Hospital Antwerp, Oncology, Edegem, Belgium Medical Oncology, Monash Medical Centre, Clayton, Australia Medical Oncology, Flinders Centre for Innovation in Cancer, Bedford Park, Australia Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Medical Oncology, Royal North Shore Hospital, St Leonards, Australia Medical Oncology, Flinders Medical Centre, Bedford Park, Australia Medical Oncology, University of Queensland, Brisbane, Australia |
Issue Date: | Apr-2018 | Date: | 2018-03-01 | Publication information: | Expert review of anticancer therapy 2018; 18(4): 339-349 | Abstract: | Oxaliplatin-based adjuvant chemotherapy has been the standard of care for resected early colon cancer for over a decade. Recent results from the IDEA meta-analysis attempt to address the question of whether 3 or 6 months of adjuvant chemotherapy is preferable in Stage III colon cancer. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of adjuvant therapy for resected early colon cancers. This article reviews the current evidence for adjuvant treatment of Stage II and III colon cancer, as well as up-to-date data regarding optimal duration of therapy. This article reviews the evidence for lifestyle modifications in the management of early colorectal cancer and other future directions for research in early colon cancer. Expert commentary: In recent years, there have been no advances in the development of novel agents for adjuvant therapy in colorectal cancer. Although the IDEA meta-analysis was negative for its primary non-inferiority endpoint, the detailed results provide valuable information that allows personalisation of treatment regimen and duration. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/17801 | DOI: | 10.1080/14737140.2018.1444481 | ORCID: | 0000-0003-0075-2176 | Journal: | Expert review of anticancer therapy | PubMed URL: | 29478352 | Type: | Journal Article | Subjects: | Colon cancer IDEA collaboration adjuvant treatment chemotherapy duration of chemotherapy |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.